
### [MONDO:0002520](http://purl.obolibrary.org/obo/MONDO_0002520)
**Label:** acute porphyria

**Subclasses:** [MONDO:0015104](http://purl.obolibrary.org/obo/MONDO_0015104) (porphyria cutanea tarda), [MONDO:0008296](http://purl.obolibrary.org/obo/MONDO_0008296) (familial porphyria cutanea tarda), [MONDO:0001676](http://purl.obolibrary.org/obo/MONDO_0001676) (erythropoietic protoporphyria), 

**Corr. equiv. classes:** [OMIM:176090](http://purl.obolibrary.org/obo/OMIM_176090), [Orphanet:443062](http://www.orpha.net/ORDO/Orphanet_443062), [Orphanet:101330](http://www.orpha.net/ORDO/Orphanet_101330), [OMIM:176100](http://purl.obolibrary.org/obo/OMIM_176100), [OMIM:177000](http://purl.obolibrary.org/obo/OMIM_177000), [OMIM:300752](http://purl.obolibrary.org/obo/OMIM_300752), [Orphanet:79278](http://www.orpha.net/ORDO/Orphanet_79278), [Orphanet:95159](http://www.orpha.net/ORDO/Orphanet_95159), 

**Class expressions from DL-Learner:**

- [HP:0010472](http://purl.obolibrary.org/obo/HP_0010472) (Abnormality of the heme biosynthetic pathway) and [HP:0012649](http://purl.obolibrary.org/obo/HP_0012649) (Increased inflammatory response) 62.50%
- [HP:0010472](http://purl.obolibrary.org/obo/HP_0010472) (Abnormality of the heme biosynthetic pathway) and [HP:0012647](http://purl.obolibrary.org/obo/HP_0012647) (Abnormal inflammatory response) 62.50%
- [HP:0010472](http://purl.obolibrary.org/obo/HP_0010472) (Abnormality of the heme biosynthetic pathway) and [HP:0011123](http://purl.obolibrary.org/obo/HP_0011123) (Inflammatory abnormality of the skin) 62.50%
- [HP:0010472](http://purl.obolibrary.org/obo/HP_0010472) (Abnormality of the heme biosynthetic pathway) and [HP:0010978](http://purl.obolibrary.org/obo/HP_0010978) (Abnormality of immune system physiology) 62.50%
- [HP:0000964](http://purl.obolibrary.org/obo/HP_0000964) (Eczema) and [HP:0010472](http://purl.obolibrary.org/obo/HP_0010472) (Abnormality of the heme biosynthetic pathway) 62.50%
- [HP:0010472](http://purl.obolibrary.org/obo/HP_0010472) (Abnormality of the heme biosynthetic pathway) and [HP:0012649](http://purl.obolibrary.org/obo/HP_0012649) (Increased inflammatory response) and [HP:0025031](http://purl.obolibrary.org/obo/HP_0025031) (Abnormality of the digestive system) 62.50%
- [HP:0010472](http://purl.obolibrary.org/obo/HP_0010472) (Abnormality of the heme biosynthetic pathway) and [HP:0012647](http://purl.obolibrary.org/obo/HP_0012647) (Abnormal inflammatory response) and [HP:0025031](http://purl.obolibrary.org/obo/HP_0025031) (Abnormality of the digestive system) 62.50%
- [HP:0010472](http://purl.obolibrary.org/obo/HP_0010472) (Abnormality of the heme biosynthetic pathway) and [HP:0011354](http://purl.obolibrary.org/obo/HP_0011354) (Generalized abnormality of skin) and [HP:0012649](http://purl.obolibrary.org/obo/HP_0012649) (Increased inflammatory response) 62.50%
- [HP:0010472](http://purl.obolibrary.org/obo/HP_0010472) (Abnormality of the heme biosynthetic pathway) and [HP:0011354](http://purl.obolibrary.org/obo/HP_0011354) (Generalized abnormality of skin) and [HP:0012647](http://purl.obolibrary.org/obo/HP_0012647) (Abnormal inflammatory response) 62.50%
- [HP:0010472](http://purl.obolibrary.org/obo/HP_0010472) (Abnormality of the heme biosynthetic pathway) and [HP:0011123](http://purl.obolibrary.org/obo/HP_0011123) (Inflammatory abnormality of the skin) and [HP:0025031](http://purl.obolibrary.org/obo/HP_0025031) (Abnormality of the digestive system) 62.50%
- [HP:0010472](http://purl.obolibrary.org/obo/HP_0010472) (Abnormality of the heme biosynthetic pathway) and [HP:0011123](http://purl.obolibrary.org/obo/HP_0011123) (Inflammatory abnormality of the skin) and [HP:0011354](http://purl.obolibrary.org/obo/HP_0011354) (Generalized abnormality of skin) 62.50%
- [HP:0010472](http://purl.obolibrary.org/obo/HP_0010472) (Abnormality of the heme biosynthetic pathway) and [HP:0011122](http://purl.obolibrary.org/obo/HP_0011122) (Abnormality of skin physiology) and [HP:0012649](http://purl.obolibrary.org/obo/HP_0012649) (Increased inflammatory response) 62.50%
- [HP:0010472](http://purl.obolibrary.org/obo/HP_0010472) (Abnormality of the heme biosynthetic pathway) and [HP:0011122](http://purl.obolibrary.org/obo/HP_0011122) (Abnormality of skin physiology) and [HP:0012647](http://purl.obolibrary.org/obo/HP_0012647) (Abnormal inflammatory response) 62.50%
- [HP:0010472](http://purl.obolibrary.org/obo/HP_0010472) (Abnormality of the heme biosynthetic pathway) and [HP:0011121](http://purl.obolibrary.org/obo/HP_0011121) (Abnormality of skin morphology) and [HP:0012649](http://purl.obolibrary.org/obo/HP_0012649) (Increased inflammatory response) 62.50%
- [HP:0010472](http://purl.obolibrary.org/obo/HP_0010472) (Abnormality of the heme biosynthetic pathway) and [HP:0011121](http://purl.obolibrary.org/obo/HP_0011121) (Abnormality of skin morphology) and [HP:0012647](http://purl.obolibrary.org/obo/HP_0012647) (Abnormal inflammatory response) 62.50%


